NOVOGEN Ltd. and Genentech entered an agreement to develop and commercialize GDC-0084, a small molecule inhibitor of the phosphoinositide-3-kinase pathway. Genentech is a member of the Roche Group. Novogen is an Australian-based company. The lead indication for GDC-0084 is glioblastoma multiforme. GDC-0084 is distinguished from most molecules in the class by its ability to cross...
More than a year after a catastrophic shortage of platinum-based chemotherapy drugs swept through the U.S., FDA on June 28 officially removed carboplatin and cisplatin from the drug shortage list.
